FPR2 and atherosclerosis: Taken together, those findings indicate a failure in the resolution of inflammation in atherosclerosis manifested by a disturbed balance between ALX/FPR2 ligands, with decreased levels of proresolving agonists and increased levels of pro-inflammatory agonists, as depicted in Figure 2.